RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 7, 2011 /PRNewswire/
— Boehringer Ingelheim and Eli Lilly and Company (NYSE:
LLY) will present the latest data from their diabetes portfolio
at the 47th Annual Meeting of the European Association for the
Study of Diabetes (EASD) in Lisbon, Portugal, September 12-16.
Study results evaluating the dipeptidyl peptidase-4 (DPP-4)
inhibitor, linagliptin, as well as the investigational
sodium-dependent glucose co-transporter-2 (SGLT-2) inhibitor,
empagliflozin (BI-10773), will be featured among the seven
presentations. Linagliptin 5 mg is marketed under the trade name
Tradjenta™ (linagliptin) tablets in the U.S. and was approved
by the U.S. Food and Drug Administration (FDA) in May 2011 to be
used along with diet and exercise to lower blood sugar in adults
with type 2 diabetes. TRADJENTA should not be used in patients with
type 1 diabetes or for the treatment of diabetic ketoacidosis
(increased ketones in the blood or urine). It has not been studied
in combination with insulin.
A long-term study evaluating the efficacy and safety of
linagliptin in patients with type 2 diabetes was selected by EASD
as an oral presentation, taking place on Friday, September 16.
The presentations are as follows: Linagliptin DataTitleFormat
AuthorsDate/TimePreclinicalDPP-4 Inhibition – A New Approach for
the Treatment of Uraemic Cardiomyopathy
Poster
824-P
L Chaykovska, K von Websky, S Heiden, J Rahnenfuhrer, T Klein, B
Hocher
Date: Tues, Sept. 13
Time: 12:30−1:30 p.m.Phase III (52-week)Long-term Efficacy
and Safety of Linagliptin in Patients with Type 2 Diabetes and
Severe Renal Impairment
Poster
821-P
J Newman, J McGill, S Patel, C Friedrich, C Sauce, H-J
Woerle
Date: Tues, Sept. 13
Time: 12:30−1:30 p.m.Phase III (pooled
analysis)Linagliptin Improves
‘/>”/>
